Skip to main navigation Skip to search Skip to main content

In vitro and in vivo performance of a dual drug-eluting stent (DDES)

  • Yingying Huang
  • , Subbu S. Venkatraman*
  • , Freddy Y.C. Boey
  • , Eeva M. Lahti
  • , P.R. Umashankar
  • , Mira Mohanty
  • , Sabareeswaran Arumugam
  • , Laxmikant Khanolkar
  • , Sudhir Vaishnav
  • *Corresponding author for this work

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

Abstract

This study reports on a dual drug-eluting stent (DDES) that has an anti-proliferative and an anti-thrombotic in a biodegradable polymer-coated onto a cobalt-chromium stent. The DDES was prepared by spray coating the bare metal stent with a biodegradable polymer loaded with sirolimus and triflusal, to treat against restenosis and thrombosis, respectively. The 2-layered dual-drug coated stent was characterized in vitro for surface properties before and after expansion, as well as for possible delamination by cross-sectioning the stent in vitro. The in vitro anti-platelet behavior of the triflusal-loaded films was investigated by using dynamic platelet adhesion measurements. Additionally, the in vitro degradation and release study of the films and the stents w/single sirolimus and dual sirolimus-triflusal in different formulations were examined. Finally, in vivo studies (in a porcine carotid artery model) were performed for acute thrombosis, inflammation and restenosis at 30 days. The in vitro results show DDES can sustain release both anti-proliferation drug (sirolimus) and anti-thrombosis drug (triflusal), two drugs were controlled in different rates to effectively reduce thrombosis and proliferation at the same time. In vivo results show a significant reduction in restenosis with dual-drug eluting stent compared with the controls (a bare metal stent, a sirolimus coated and a pure polymer-coated stent). The reduction in restenosis with a dual sirolimus-triflusal eluting stent is associated with an inhibition of inflammation, especially thrombus formation, suggesting that such dual-drug eluting stents have a role to play for the treatment of coronary artery disease. © 2010 Elsevier Ltd.
Original languageEnglish
Pages (from-to)4382-4391
JournalBiomaterials
Volume31
Issue number15
Online published26 Feb 2010
DOIs
Publication statusPublished - May 2010
Externally publishedYes

Funding

We acknowledge the Director, SCTIMST and Head, BMT Wing, SCTIMST for providing infrastructure and other support for conducting this study. We are also grateful for extensive support from Aditya Kharkar of Insightra Medical Pvt. Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Keywords

  • Cobalt alloy
  • Drug release
  • Restenosis
  • Stent
  • Thrombosis

Fingerprint

Dive into the research topics of 'In vitro and in vivo performance of a dual drug-eluting stent (DDES)'. Together they form a unique fingerprint.

Cite this